Remove FDA Approval Remove FDA Compliance Remove Genetics
article thumbnail

FDA Refines Accelerated Approval Pathway with New Draft Guidance

XTalks

Programs like the Rare Disease Endpoint Advancement Pilot encourage collaboration with the FDA to establish novel surrogate endpoints. This initiative is particularly impactful for rare diseases and genetic disorders, where traditional endpoints may be infeasible.